DocGo (DCGO) Earnings Date & Reports

Key Takeaways

• DocGo reported third quarter 2026 revenue of $73.4 million, up 3.7% year over year but below Wall Street's roughly $78.7 million consensus estimate.
• Net loss narrowed to $18.1 million from $29.7 million a year earlier, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of $3.2 million from a loss of $7.2 million.
• Diluted loss per share of $0.17 came in wider than the approximately $0.09 loss that analysts had expected.
• Medical transportation revenue reached a quarterly record of $53.3 million, while Mobile Health revenue declined slightly to $20.2 million.
• Management cut full-year 2026 revenue guidance to approximately $300 million and kept adjusted EBITDA guidance unchanged at a loss of $17 million to $22 million.
• The company also announced a CEO transition, with the board launching a search as Lee Bienstock's contract nears its December 31, 2026 expiration.
• For more detail on DocGo's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated ticker pages.
• You can also explore Trending AI Robots to see AI-driven trading strategies and market ideas.

Earnings Context and Why It Matters

DocGo's third quarter 2026 results arrive at a pivotal moment for the mobile health and medical transportation provider. The company has spent the past year restructuring away from its former migrant-services business and refocusing on higher-margin core offerings such as medical transportation, remote patient monitoring, mobile phlebotomy, and virtual care through its SteadyMD acquisition. Investors are watching closely to see whether these efforts translate into narrowing losses and a clearer path toward profitability. Because management has also guided to continued adjusted EBITDA losses through 2026, this report serves as a key checkpoint on execution, cost discipline, and cash management — factors that will shape sentiment as the company navigates a leadership transition and pursues additional acquisitions.

Reported Results

For the quarter ended September 30, 2026, DocGo reported total revenue of $73.4 million, a 3.7% increase from $70.8 million in the prior-year period, but below the consensus estimate of approximately $78.7 million. Revenue excluding migrant-related programs grew about 18% year over year, driven by the SteadyMD acquisition, which contributed roughly $7.8 million during the quarter.

Net loss was $18.1 million, an improvement from a net loss of $29.7 million in the third quarter of 2025. Adjusted EBITDA was a loss of $3.2 million, compared with a loss of $7.2 million a year earlier. On a per-share basis, the company reported a diluted loss of $0.17, wider than the roughly $0.09 loss that analysts had anticipated.

Gross margin showed progress. GAAP (Generally Accepted Accounting Principles) gross margin improved to 29.7% from 20.0%, while adjusted gross margin — which strips out depreciation and amortization — was 33.3%, roughly in line with 33.0% a year earlier. Medical transportation revenue reached $53.3 million, up 6.4% from $50.1 million, while Mobile Health revenue was $20.2 million, down slightly from $20.7 million. For the full year, management revised revenue guidance to approximately $300 million, down from $305 million to $310 million, citing the restructuring of unprofitable business lines, while reaffirming its adjusted EBITDA outlook of a $17 million to $22 million loss.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for both retail and professional investors looking to streamline their research workflow.

Market Reaction and Investor Sentiment

DocGo shares fell roughly 6.6% in after-hours trading following the release, reflecting investor disappointment that revenue and per-share results both came in short of Wall Street's expectations. The mixed quarter highlighted the tension between steady operational progress and lingering losses: while medical transportation volumes reached record levels and gross margins improved, the company still posted a net loss and trimmed its revenue outlook. The simultaneous announcement of a CEO search added a layer of uncertainty for shareholders, even as management emphasized that the transition is being handled through an executive search firm and that Bienstock has agreed to remain through at least March 31, 2027 to support continuity.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether DocGo can sustain its margin trajectory and reach the profitability milestones management has described. The company reaffirmed its full-year 2026 adjusted EBITDA guidance of a $17 million to $22 million loss, implying continued improvement in the fourth quarter and into 2027.

Several catalysts are worth monitoring. First, the pending acquisition of Hicuity Health is expected to close in late November or early December and is not yet included in revenue guidance, meaning it could add incremental scale to the Mobile Health segment. Second, the company's decision to wind down its unprofitable Upstate New York medical transportation market should remove a drag on gross margins going forward.

Cost pressures remain a factor to watch. Elevated fuel costs and aggressive hiring to support SteadyMD demand have restrained margins, and management's ability to normalize those expenses will be central to the profitability story. Finally, the leadership transition and any further restructuring or strategic alternatives activity could influence the pace and direction of the turnaround. As always, actual results will depend on execution, contract ramps with payer and provider partners, and broader healthcare and economic conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations